Tue, Apr 9th 2024
Novartis announces job reductions, impacting development roles in Switzerland and the US. Plans for new roles in Basel.
The pharmaceutical company Novartis is facing job cuts. The development organisation (Development) will be affected, as the company announced on Tuesday.
In Switzerland, 400 to 440 developments are likely to fall victim to the measures over the next two to three years.
“In addition to the potential impact of up to 440 jobs in Switzerland, we anticipate that up to 240 jobs in the US could be affected,” Novartis said.
The development department in the USA currently has around 2000 jobs. In addition to Basel, the USA will remain an important development location for Novartis.
According to Novartis, restructuring has become necessary as a result of the Group’s transformation over the past few years. The spin-off of the generics division Sandoz last October was the final step in the transition to a focused pharmaceutical group that is oriented towards five core therapeutic areas.
After the Group cut 8,000 of its then total of 108,000 jobs worldwide just two years ago, the current round affects the division responsible for tasks such as regulatory affairs and technical research and development. The research organisation (Biomedical Research) is not affected by the measures.
Novartis emphasises that it will not only be cutting jobs, but also creating new ones. In Basel, the development department will create up to 40 new jobs in 2024 to support the acquisition of Chinook, the license agreement with Argo Biopharma and the development of radioligand therapy as well as the capacities for x-RNA at Technical Research and Development.
After Switzerland had accounted for around 10 to 11% of the Novartis workforce in recent years, the Swiss share is now over 13% since the Sandoz spin-off.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic